Stay updated with breaking news from Nasdaq Prtk. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 234,863 shares of the business’s stock in a transaction that occurred on Friday, March 17th. The shares were purchased at an average cost of $1.50 per share, with a total value of $352,294.50. Following the completion of the acquisition, the insider now […]
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero purchased 105,137 shares of the firm’s stock in a transaction on Monday, March 20th. The stock was bought at an average price of $1.40 per share, for a total transaction of $147,191.80. Following the completion of the transaction, the insider now directly owns […]
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) major shareholder James D. Dondero bought 106,000 shares of the business’s stock in a transaction on Wednesday, March 22nd. The shares were acquired at an average cost of $1.77 per share, for a total transaction of $187,620.00. Following the purchase, the insider now directly owns 2,056,000 shares in […]
Paratek Pharmaceuticals (NASDAQ:PRTK – Get Rating) had its target price lowered by HC Wainwright from $20.00 to $10.00 in a research report sent to investors on Monday morning, The Fly reports. HC Wainwright also issued estimates for Paratek Pharmaceuticals’ Q1 2023 earnings at ($0.27) EPS, Q2 2023 earnings at ($0.24) EPS, Q3 2023 earnings at […]
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK – Get Rating) – Equities researchers at HC Wainwright lowered their Q1 2023 earnings estimates for Paratek Pharmaceuticals in a report issued on Monday, March 20th. HC Wainwright analyst E. Arce now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.27) for the quarter, down from their […]